Biliary Tract Cancer Clinical Trials in Portland, Oregon

4 studies are recruiting for biliary tract cancer in Portland, Oregon right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

    The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local reg…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Oregon Health and Science University, Portland, Oregon
    Locations
    185 in total
    Run by
    Jazz Pharmaceuticals

    See if you can join NCT06282575 on ClinicalTrials.gov

  2. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Providence Portland Medical Center, Portland, Oregon
    Locations
    26 in total
    Run by
    SystImmune Inc.

    See if you can join NCT06293898 on ClinicalTrials.gov

  3. A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

    The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Portland, Oregon
    Locations
    177 in total
    Run by
    AstraZeneca

    See if you can join NCT07221253 on ClinicalTrials.gov

  4. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

    TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

    Stage
    Phase 2
    Ages
    18 to 130
    Site
    Research Site, Portland, Oregon
    Locations
    96 in total
    Run by
    AstraZeneca

    See if you can join NCT05489211 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.